Parenteral Nutrition Market Size, Share & Trends Analysis Report By Nutrient Type (Single Dose Amino Acid Solution, Parenteral Lipid Emulsion), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2021 - 2028

Report Overview

The global parenteral nutrition market size was valued at USD 6.0 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.9% from 2021 to 2028. Some of the major factors anticipated to drive the demand for parenteral nutrition include the increasing prevalence of malnutrition among children, particularly in developing and under-developed countries globally. In addition, the need for parenteral nutrition (PN) to properly balance lipids, amino acids, minerals, vitamins, and other nutrients is fueling the market growth. Parenteral drug administration provides the benefit of fast action and lower dose delivery that prevents various adverse effects because of dietary imbalances, thereby promoting the growth of PN products. Diseases such as esophageal cancer, head & neck cancer, Crohn's, gastric cancer, ulcerative colitis, and laryngeal cancer affect oral food intake among patients. Their growing prevalence is, in turn, expected to drive the demand for parenteral nutrition. However, the high risk of infection during administration and the growing preference among patients for enteral nutrition are few key constraints of this market.

The surge in the prevalence of chronic conditions and hospital-acquired malnutrition, along with the rapid growth of the geriatric population, is accountable for the market growth. The increase in natality is a key impact-rendering driver for the market over the forecast period. In addition, benefits associated with the adoption of parenteral nutrition products, including the ease of use and the ability to stimulate stomach blood flow, avoid bacteria, provide more efficient nutrients, and preserve muscle catabolism. The awareness created by various government bodies is also likely to help increase the demand for these products. For instance, educational campaigns are carried out for spreading health awareness and initiatives are undertaken to promote health and social care, with a growing emphasis on nutrition.

PN is also prescribed to infants and children requiring special nutritional management due to a disease or medical condition. Specialized Nutrition Europe (SNE) states that around 300,000 children in the EU would require medical nutrition for special medical purposes in the early stages of their life to support growth and development. It also states that around 40% of the adult patients in hospitals are malnourished and require medical nutrition for the management of disease-related malnutrition, which would help reduce the duration of hospital stay. PN lowers the risk of infection and underdevelopment, which promotes its adoption. The demand for PN products is higher in Very-Low-Birth-Weight (VLBW) newborns owing to the low prospect of Enteral Nutrition (EN). In addition, increasing adoption of PN for premature infants leads to faster neurological development, minimized risk of complications, and improved intrauterine nutrient deposition, thereby improving their chance of survival. 

COVID-19 Parenteral Nutrition Market: 6.8% increase in revenue from 2019 to 2020

The ongoing COVID-19 pandemic has significantly increased the adoption of PN to provide adequate nutrition and fluids required by the body for faster and safer recovery. The growing adoption of the parenteral mode of administration over enteral feeding among COVID-19 patients for meeting appropriate nutritional requirements, increasing nutrient absorption, and reducing infection risk is contributing to market growth. In addition, increasing adoption of these formulations among clinicians for helping patients reach their target nutrition intake, improve recovery, and minimize hospital stays are fueling the market growth.

In addition, a growing number of initiatives undertaken by government and healthcare organizations to raise awareness regarding the importance of a balanced nutritional value in the body is one of the key factors boosting market growth. The government investments to provide nutritional supplements to malnourished children are further anticipated to drive the market across the globe. For instance, the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on parenteral nutrition in pediatrics recommend the use of parenteral lipid emulsions as soon as possible after birth for small preterm infants, when enteral nutrition is not possible, for reducing the possibility of postnatal growth failure.

Nutrient Type Insights

In 2020, single-dose amino acid solution accounted for the largest share of 31.0%. This is attributed to the adoption of these products, along with vitamins, dextrose, and trace minerals, for maintaining weight equilibrium among the undernourished population. In addition, the increased use of amino acid solutions can be attributed to the availability of solutions with fewer adverse effects, resulting in improved patient outcomes and an increase in the influx of regulatory authorized solutions.

The parenteral lipid emulsion segment is anticipated to register the fastest growth rate during the forecast period. An increase in the prevalence of hospital malnutrition is one of the key factors expected to propel the demand for parenteral lipid emulsions in delivering nonprotein calories and essential fatty acids in patients, reducing inflammation, and improving metabolic and clinical outcomes.  Moreover, the surge in demand from critically ill patients and the high prevalence of chronic diseases, including diabetes, cancer, and inflammatory bowel disease, are the key factors expected to drive adoption in hospitals.

Regional Insights

North America accounted for the largest share of 41.7% in 2020. This can be attributed to the availability of technologically advanced medical devices, high research expenditure by government agencies and private entities in the healthcare sector, and collaborations among universities, regulatory authorities, and the medical device industry. Increasing demand for home health care products is one of the major drivers for this market as PN products are available in clinical care and home health care. The growing geriatric population, coupled with the increasing prevalence of chronic diseases, like cancer, gastrointestinal tract failures, and cardiovascular problems, is further anticipated to drive the regional market.

Asia Pacific is anticipated to register the fastest growth rate during the forecast period. Market expansion is expected to be fueled by economic development in countries, such as India, China, and Japan, and favorable government efforts associated with the reimbursement policies and development of healthcare infrastructure. In addition, the increasing prevalence of chronic diseases, the growing awareness about the benefits of the nutrient types, and the increasing number of PN users in some of the prominent countries of the region are boosting the growth of the industry in the region.

Key Companies & Market Share Insights

Some of the market players are continuously investing in the development of advanced PN options to gain a competitive advantage over others in the market, which is expected to drive the market. For instance, in December 2018, Fresenius Kabi announced the commercial availability of Omegaven (fish oil triglycerides), an FDA-approved fish oil lipid emulsion in the U.S. The nutrient type is aimed at filling the critical gap among pediatric patients with parenteral nutrition-associated cholestasis (PNAC) by delivering fatty acids and calories. In addition, they are adopting various strategies such as mergers and acquisitions and the expansion of manufacturing facilities to strengthen their businesses and expand their nutrient type reach. Some prominent players in the global parenteral nutrition market include:

• Baxter

• Grifols, S.A.

•  Allergan

• Otsuka Pharmaceutical Factory, Inc.

• Actavis Inc.

• B. Braun Melsungen AG

•  Fresenius Kabi AG

• ViforPharma

•  Sichuan Kelun Pharmaceutical Co., Ltd.

•  Pfizer Inc. (Hospira Inc.)

Parenteral Nutrition Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global parenteral nutrition market report on the basis of nutrient type and region:

• Nutrient Type Outlook (Revenue, USD Million, 2016 - 2028)

  • Carbohydrates

  • Parenteral Lipid Emulsion

  • Single Dose Amino Acid Solution

  • Trace Elements

  • Vitamins & Minerals

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • Italy

    • France

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE